Capital Performance Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Capital Performance Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$673K	Sell	1,355 -102	-7%	-$45.2K	0.04%	139
2026 Q1	$651K	Buy	1,457 +807	+124%	+$376K	0.04%	179
2025 Q4	$295K	Buy	650 +21	+3%	+$9.05K	0.02%	319
2025 Q3	$246K	Buy	629 +28	+5%	+$11.7K	0.04%	268
2025 Q2	$267K	Buy	601 +59	+11%	+$27.2K	0.05%	178
2025 Q1	$263K	Buy	+542	New	+$253K	0.06%	181
2024 Q4	–	Sell	-83	Closed	-$38.5K	–	2634
2024 Q3	$38.5K	Buy	+83	New	+$39.9K	0.01%	420

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Capital Performance Advisors's VRTX Position: Q2 2026 in Review

Capital Performance Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 7% in Q2 2026, selling an estimated $45.2K and leaving 1,355 shares worth $673K. The position accounts for 0.04% of the portfolio, ranked #139.

Capital Performance Advisors first reported a position in VRTX in Q3 2024 and has held it in 7 quarters since. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Capital Performance Advisors held 1,355 shares of Vertex Pharmaceuticals worth $673K as of Q2 2026.
Capital Performance Advisors sold 102 Vertex Pharmaceuticals shares in Q2 2026, an estimated $45.2K.
Vertex Pharmaceuticals made up 0.04% of Capital Performance Advisors's portfolio in Q2 2026, its #139 holding.
Capital Performance Advisors first reported a position in Vertex Pharmaceuticals in Q3 2024 and has held it in 7 quarters since.
1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Capital Performance Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.